Jang, Minyoung
Simoens, Steven http://orcid.org/0000-0002-9512-2005
Kwon, Taeksang http://orcid.org/0000-0002-7766-0141
Funding for this research was provided by:
Celltrion Healthcare
Article History
Accepted: 30 November 2020
First Online: 24 December 2020
Declarations
:
: Celltrion Healthcare.
: SS is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund); was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer, and MSD; has participated in advisory board meetings for Pfizer and Amgen; has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma, and Pfizer; and has had speaker engagements for Celltrion, Sandoz, and Amgen. MJ and TK have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The data that support the findings of this study are available from the corresponding author, TSK, upon reasonable request.
: Not applicable.
: Model programming and medical writing support was provided by IQVIA.